CS
BPMC

Credit Suisse’s Blueprint Medicines BPMC Stock Holding History

Credit Suisse’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-10,000
Closed -$539K – 3986
2018
Q4 		$539K Buy
+10,000
New +$608K ﹤0.01% 3206

Other funds holding BPMC

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Credit Suisse's BPMC Position: Q1 2024 in Review

Credit Suisse increased its Blueprint Medicines (BPMC) stake by 1.1% in Q1 2024, buying an estimated $62.5K and bringing the position to 69,100 shares worth $6.55M. The position accounts for 0.01% of the portfolio, ranked #1153.

Credit Suisse first reported a position in BPMC in Q2 2016 and has held it in 32 quarters since. The position peaked at $11.2M in Q4 2019. 283 funds tracked by Wall St. Rank hold BPMC as of Q1 2024.

  • Credit Suisse held 69,100 shares of Blueprint Medicines worth $6.55M as of Q1 2024.
  • Credit Suisse bought 729 Blueprint Medicines shares in Q1 2024, an estimated $62.5K.
  • Blueprint Medicines made up 0.01% of Credit Suisse's portfolio in Q1 2024, its #1153 holding.
  • Credit Suisse first reported a position in Blueprint Medicines in Q2 2016 and has held it in 32 quarters since.
  • Credit Suisse's Blueprint Medicines position peaked at $11.2M in Q4 2019.
  • 283 funds tracked by Wall St. Rank held Blueprint Medicines as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.